2/21/19 1
Update in CNS Infections
Brian Schwartz, MD Division of Infectious Diseases, UCSF
Outline
- Infections of the Brain
- Infections of the Spine
Outline
- Infections of the Brain
- Infections of the Spine
Outline in CNS Infections Infections of the Brain Infections of - - PDF document
2/21/19 Update Outline in CNS Infections Infections of the Brain Infections of the Spine Brian Schwartz, MD Division of Infectious Diseases, UCSF Outline Infections of the Brain Infections of the Spine 1 2/21/19 Case
Brian Schwartz, MD Division of Infectious Diseases, UCSF
had progressive lethargy, fever, and stiff neck x 48 hrs.
DISCUSS
Hasbun R. NEJM. 2001. Gopal AK. Arch Int Med. 1999.
18–34 Yr 35–49 Yr 50–64 Yr ≥65 Yr All adult cases Percentage of Total Cases 100 80 90 70 60 40 30 10 50 20
Thigpen MC. NEJM.2011
Streptococcus pneumoniae Neisseria meningitidis GBS Haemophilus influenzae Listeria monocytogenes
Risk factor Pathogens Antimicrobials 2-50 yr
Vancomycin + Ceftriaxone > 50 yr
Vancomycin+ Ceftriaxone + Ampicillin
Adapted from Tunkel AR. CID 2004
1 2 3 4 5 6 5 10 24
Colony forming units/ml CSF Hours post initiation of therapy CFTX RIF VANCO + RIF VANCO CFTX + Vanco
Tunkel et al, CID 2004:39.
de Gans J. NEJM 2002
Dex Placebo RR of poor outcome
All
15% 25% 0.59 (0.37-0.94), p=0.03
26% 52% 0.50 (0.30-0.83), p=0.006
8% 11% 0.75 (0.21-2.63), p=0.74
20 40 60 80 100 0-2 2.1-4 4.1-6 6.1-24 24.1-48 >48
% of CSF sterilized
Time after start of antibiotics (hours)
Kanegye JT . Pediatrics.
Wu et al. BMC Infectious Diseases. 2013
Pathogen Primary Duration
10-14 days
Pen MIC ≤0.1 µg/ml Penicillin Pen MIC 0.1-1.0 µg/ml Ceftriaxone Pen MIC >0.1-1.0 µg/ml Vanco + Ceftriaxone
7 days
Pen MIC ≤0.1 µg/ml Penicillin G Pen MIC 0.1-1.0 µg/ml Ceftriaxone
Ampicillin
≥21 days
Adapted from Tunkel AR. CID 2004
YES NO Blood cx + Lumbar puncture Blood cx Steroids and empiric antimicrobials Steroids and empiric antimicrobials CSF suggestive of bacterial meningitis Head CT w/o mass lesion or herniation Lumbar puncture Refine therapy
Tunkel AR. CID 2004
Pathogen Alternative treatment
Meropenem or fluoroquinolone
Aztreonam, fluoroquinolone
TMP-SMX, meropenem
Adapted from Tunkel AR. CID 2004
http://www.cdc.gov/MMWR/preview/mmwrhtml/00046263.htm
Case by Jen Babik
WBCs
PMNs
Glucose
(CSF/serum)
Protein
(mg/dL)
Bacterial meningitis 500- 10K >85 < 0.4 < 200 Aseptic meningitis 10-500 <50 WNL <100 Encephalitis 0-1000 <50 WNL < 100 Chronic meningitis 100-500 <50 < 0.4 > 200 DDx Aseptic Meningitis/Lymphocytic Pleocytosis
(brain/epidural abscess)
sarcoid)
Diagnostics:
Case by Jen Babik
Case created by Jen Babik
WBCs
PMNs %
Glucose
(CSF/serum)
Protein
(mg/dL)
Bacterial meningitis 500- 10K >85 < 0.4 < 200 Aseptic meningitis 10-500 <50 WNL <100 Encephalitis 0-1000 <50 WNL < 100 Chronic meningitis 100-500 <50 < 0.4 > 200
erythema/TTP
Nolla JM. Arthritis and Rheumatisim. 2002
S aureus 48% GNR 23%
Strep 9% Polymicrobial 8% S epi 7% Other 5%
McHenry et al CID 2002
Bernard et al. Lancet. 2015
6 wk (%) 12 wk (%) (n) 176 175 Cure 160 (91) 159 (91)
consistent with discitis/osteomyelitis
no constitutional symptoms